Literature DB >> 11082383

A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery.

J P Breinholt1, J A Hawkins, L M Lambert, T C Fuller, T Profaizer, R E Shaddy.   

Abstract

BACKGROUND: The purpose of this study was to prospectively determine the immunogenicity of nonvalved allograft tissue used to repair congenital heart defects. METHODS AND
RESULTS: We prospectively analyzed the immune response of 11 children, 1.4 months to 10 years of age, who required nonvalved allografts to alleviate stenosis during repair of congenital heart defects. In 7 patients, pulmonary arterial grafts were used; in 3 patients, monocusp pulmonary artery grafts were used; and in 1 patient, a section of glutaraldehyde-preserved allograft pericardium was used. We measured the level of HLA panel-reactive antibody (PRA) before surgery, 1 week after, 1 month after, and 3 months after surgery. PRA was determined by the antiglobulin technique and flow cytometry. HLA class I and class II antibodies measured by either technique were negligible before and 1 week after surgery. Nine of 11 patients (82%) exhibited a significant immune response at 1 month after surgery that further increased at 3 months. The measured PRA for class I antibodies with the antiglobulin technique increased to 43+/-36% at 1 month and to 69+/-38% at 3 months after surgery. Flow cytometry class I PRA measurements were similar. Class II PRA increased to 26+/-34% at 1 month and to 41+/-36% at 3 months. Age negatively correlated with the degree of elevation of PRA, but neither allograft area nor the area indexed to patient body surface area correlated with PRA.
CONCLUSIONS: Cryopreserved nonvalved allografts induce a strong HLA antibody response in the majority of children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082383     DOI: 10.1161/01.cir.102.suppl_3.iii-179

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Decellularized aortic conduits: could their cryopreservation affect post-implantation outcomes? A morpho-functional study on porcine homografts.

Authors:  Michele Gallo; Antonella Bonetti; Helen Poser; Filippo Naso; Tomaso Bottio; Roberto Bianco; Adolfo Paolin; Paolo Franci; Roberto Busetto; Anna Chiara Frigo; Edward Buratto; Michele Spina; Maurizio Marchini; Fulvia Ortolani; Laura Iop; Gino Gerosa
Journal:  Heart Vessels       Date:  2016-04-26       Impact factor: 2.037

2.  Safety profile of decellularized, cryopreserved pulmonary allografts when used in the aortic position for neonatal arch reconstruction.

Authors:  Marc D Knepp; Richard G Ohye; Robert J Gajarski
Journal:  Pediatr Cardiol       Date:  2011-04-11       Impact factor: 1.655

Review 3.  Will catheter interventions replace surgery for valve abnormalities?

Authors:  Michael L O'Byrne; Matthew J Gillespie
Journal:  Curr Opin Cardiol       Date:  2014-01       Impact factor: 2.161

4.  Right ventricle to pulmonary artery conduit augmentation compared with replacement in young children.

Authors:  Justin P V Zachariah; Frank A Pigula; John E Mayer; Doff B McElhinney
Journal:  Ann Thorac Surg       Date:  2009-08       Impact factor: 4.330

Review 5.  Immunologic considerations in heart transplantation for congenital heart disease.

Authors:  Beth D Kaufman; Robert E Shaddy
Journal:  Curr Cardiol Rev       Date:  2011-05

Review 6.  Current Desensitization Strategies in Heart Transplantation.

Authors:  Marlena V Habal
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 8.786

7.  Donor-specific HLA antibodies after fresh decellularized vs cryopreserved native allograft implantation.

Authors:  Iuliana Coti; Sabine Wenda; Alexandra Andreeva; Alfred Kocher; Guenther Laufer; Gottfried Fischer; Martin Andreas
Journal:  HLA       Date:  2020-10-13       Impact factor: 4.513

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.